Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.30 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6580427 | 1.00 | PPARA (0.37) | PPARAERBB2MINK1PTGDR2PPARG | |
| SCHEMBL3677614 | 0.90 | ERBB2 (0.44) | ERBB2MINK1FFAR1 | |
| SCHEMBL3677617 | 0.90 | ERBB2 (0.44) | ERBB2MINK1FFAR1 | |
| SCHEMBL3682995 | 0.85 | ERBB2 (0.52) | PPARAERBB2MINK1PPARG | |
| SCHEMBL3682992 | 0.85 | ERBB2 (0.52) | PPARAERBB2MINK1PPARG | |
| SCHEMBL6582396 | 0.82 | ERBB2 (0.44) | PPARAERBB2MINK1PPARGFFAR1 | |
| SCHEMBL6582402 | 0.82 | ERBB2 (0.44) | PPARAERBB2MINK1PPARGFFAR1 | |
| SCHEMBL6976396 | 0.82 | PPARA (0.40) | PPARAERBB2MINK1PPARGCYSLTR2 | |
| SCHEMBL6584346 | 0.81 | ERBB2 (0.46) | ERBB2MINK1FFAR1 | |
| SCHEMBL6584353 | 0.81 | ERBB2 (0.46) | ERBB2MINK1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138160-A1 | Preventive/therapeutic method for cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040116330-A1 | Diagnosing or specifying a growth factor receptor expressed in cancer cells, and selectively inhibiting all or a part of the growth factor receptor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-17 | — | — | US | disclosed |
| US-6716863-B2 | TYROSINE KINASE INHIBITORS; ANTITUMOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| US-20040058956-A1 | Pharmaceutical composition having an improved water solubility | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| US-20040053972-A1 | Medicinal compositions having improved absorbability | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20040024035-A1 | Heterocyclic compounds, their production and use | TASAKA AKIHIRO (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1350792-A1 | MEDICINAL COMPOSITIONS IMPROVED IN SOLUBLITY IN WATER | Takeda Chemical Industries, Ltd. (JP) | 2003-10-08 | — | — | EP | disclosed |
| EP-1350793-A1 | MEDICINAL COMPOSITIONS HAVING IMPROVED ABSORBABILITY | Takeda Chemical Industries, Ltd. (JP) | 2003-10-08 | — | — | EP | disclosed |
| US-20020173526-A1 | Heterocyclic compounds their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024035-A1 | Heterocyclic compounds, their production and use | ABL1, ROS1, MAPK1 | PPARA 3705/4885ERBB2 6/4885MINK1 340/4885 |
| US-20020173526-A1 | Heterocyclic compounds their production and use | ABL1, ROS1, MAPK1 | PPARA 4010/4885ERBB2 8/4885MINK1 258/4885 |
| US-20040058956-A1 | Pharmaceutical composition having an improved water solubility | ERBB2, EGFR, ABCG2 | PPARA 2455/4885ERBB2 1/4885MINK1 3888/4885 |
| US-20040138160-A1 | Preventive/therapeutic method for cancer | EGFR, ERBB2, ERBB3 | PPARA 633/4885ERBB2 2/4885MINK1 2919/4885 |
| US-20040053972-A1 | Medicinal compositions having improved absorbability | EGFR, ERBB2, ERBB3 | PPARA 2800/4885ERBB2 2/4885MINK1 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.